Table 1.

Phase 2/3 clinical trials with pGC- and sGC-modulating drugs in cardiovascular diseases and chronic heart failure

ME	Phase	Indication	NCT number	Study name	Status	Reference
Sac/Val; LCZ696	2	HFpEF	NCT00887588	PARAMOUNT	Completed	Solomon et al. 2012
Sac/Val; LCZ696	2	HFrEF	NCT01922089	TITRATION	Completed	Senni et al. 2016
Sac/Val; LCZ696	3	HFrEF	NCT01035255	PARADIGM-HF	Completed/approved	McMurray et al. 2014
Sac/Val; LCZ696	3	HFpEF	NCT01920711	PARAGON-HF	Completed	Solomon et al. 2019
Riociguat	2	PH-LVD	NCT01065454	LEPHT	Completed	Bonderman et al. 2013
Vericiguat	2	HFrEF	NCT01951625	SOCRATES-Reduced	Completed	Gheorghiade et al. 2015
Vericiguat	2	HFpEF	NCT01951638	SOCRATES-Preserved	Completed	Pieske et al. 2017
Vericiguat	3	HFrEFa	NCT02861534	VICTORIA-HFrEF	Ongoing	Armstrong et al. 2018
Vericiguat	3	HFpEFa	NCT03547583	VITALITY-HFpEF	Ongoing	Butler et al. 2019
Praliciguat	2	T2D and HTN	NCT03091920		Completed
Praliciguat	2	T2D and HTN	NCT02906579		Completed
Praliciguat	2	HFpEF	NCT03254485	CAPACITY-HFpEF	Ongoing
Praliciguat	2	Diabetic nephrop.	NCT03217591		Ongoing

^aBayer AG/MSD codevelopment of vericiguat